vs

Side-by-side financial comparison of Citizens Community Bancorp Inc. (CZWI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $15.8M, roughly 1.2× Citizens Community Bancorp Inc.). Citizens Community Bancorp Inc. runs the higher net margin — 27.1% vs -177.4%, a 204.5% gap on every dollar of revenue. On growth, Citizens Community Bancorp Inc. posted the faster year-over-year revenue change (14.9% vs -11.5%). Citizens Community Bancorp Inc. produced more free cash flow last quarter ($10.4M vs $-23.1M). Over the past eight quarters, Citizens Community Bancorp Inc.'s revenue compounded faster (1.9% CAGR vs -12.2%).

Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CZWI vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$15.8M
CZWI
Growing faster (revenue YoY)
CZWI
CZWI
+26.3% gap
CZWI
14.9%
-11.5%
LAB
Higher net margin
CZWI
CZWI
204.5% more per $
CZWI
27.1%
-177.4%
LAB
More free cash flow
CZWI
CZWI
$33.5M more FCF
CZWI
$10.4M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CZWI
CZWI
Annualised
CZWI
1.9%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CZWI
CZWI
LAB
LAB
Revenue
$15.8M
$19.6M
Net Profit
$4.3M
$-34.7M
Gross Margin
48.5%
Operating Margin
31.0%
-168.5%
Net Margin
27.1%
-177.4%
Revenue YoY
14.9%
-11.5%
Net Profit YoY
58.1%
-28.8%
EPS (diluted)
$0.44
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZWI
CZWI
LAB
LAB
Q4 25
$15.8M
Q3 25
$16.2M
$19.6M
Q2 25
$16.1M
$21.8M
Q1 25
$14.2M
$40.8M
Q4 24
$13.7M
Q3 24
$14.2M
$22.1M
Q2 24
$13.5M
$22.5M
Q1 24
$15.2M
$45.5M
Net Profit
CZWI
CZWI
LAB
LAB
Q4 25
$4.3M
Q3 25
$3.7M
$-34.7M
Q2 25
$3.3M
$-33.5M
Q1 25
$3.2M
$-26.0M
Q4 24
$2.7M
Q3 24
$3.3M
$-26.9M
Q2 24
$3.7M
$-45.7M
Q1 24
$4.1M
$-32.2M
Gross Margin
CZWI
CZWI
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
CZWI
CZWI
LAB
LAB
Q4 25
31.0%
Q3 25
27.9%
-168.5%
Q2 25
25.1%
-118.1%
Q1 25
28.0%
-80.8%
Q4 24
24.5%
Q3 24
29.5%
-120.9%
Q2 24
35.0%
-134.5%
Q1 24
34.2%
-132.2%
Net Margin
CZWI
CZWI
LAB
LAB
Q4 25
27.1%
Q3 25
22.7%
-177.4%
Q2 25
20.3%
-153.7%
Q1 25
22.5%
-63.8%
Q4 24
19.7%
Q3 24
23.1%
-122.0%
Q2 24
27.2%
-203.3%
Q1 24
26.9%
-70.6%
EPS (diluted)
CZWI
CZWI
LAB
LAB
Q4 25
$0.44
Q3 25
$0.37
$-0.09
Q2 25
$0.33
$-0.09
Q1 25
$0.32
$-0.07
Q4 24
$0.28
Q3 24
$0.32
$-0.07
Q2 24
$0.35
$-0.12
Q1 24
$0.39
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZWI
CZWI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$118.9M
$129.4M
Total DebtLower is stronger
$51.8M
Stockholders' EquityBook value
$187.9M
$399.7M
Total Assets
$1.8B
$539.6M
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZWI
CZWI
LAB
LAB
Q4 25
$118.9M
Q3 25
$82.4M
$129.4M
Q2 25
$67.5M
$158.6M
Q1 25
$100.2M
$150.9M
Q4 24
$50.2M
Q3 24
$36.6M
$210.6M
Q2 24
$36.9M
$269.8M
Q1 24
$28.6M
$287.1M
Total Debt
CZWI
CZWI
LAB
LAB
Q4 25
$51.8M
Q3 25
Q2 25
Q1 25
Q4 24
$66.6M
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CZWI
CZWI
LAB
LAB
Q4 25
$187.9M
Q3 25
$186.8M
$399.7M
Q2 25
$183.5M
$424.5M
Q1 25
$180.1M
$454.6M
Q4 24
$179.1M
Q3 24
$180.1M
$489.3M
Q2 24
$176.0M
$510.3M
Q1 24
$172.8M
$577.3M
Total Assets
CZWI
CZWI
LAB
LAB
Q4 25
$1.8B
Q3 25
$1.7B
$539.6M
Q2 25
$1.7B
$557.0M
Q1 25
$1.8B
$579.6M
Q4 24
$1.7B
Q3 24
$1.8B
$681.5M
Q2 24
$1.8B
$708.7M
Q1 24
$1.8B
$777.7M
Debt / Equity
CZWI
CZWI
LAB
LAB
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
0.37×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZWI
CZWI
LAB
LAB
Operating Cash FlowLast quarter
$11.7M
$-22.2M
Free Cash FlowOCF − Capex
$10.4M
$-23.1M
FCF MarginFCF / Revenue
65.9%
-118.1%
Capex IntensityCapex / Revenue
8.3%
4.5%
Cash ConversionOCF / Net Profit
2.74×
TTM Free Cash FlowTrailing 4 quarters
$17.5M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZWI
CZWI
LAB
LAB
Q4 25
$11.7M
Q3 25
$6.6M
$-22.2M
Q2 25
$-406.0K
$-20.7M
Q1 25
$1.6M
$-30.3M
Q4 24
$20.4M
Q3 24
$3.5M
$-27.9M
Q2 24
$5.1M
$-39.0M
Q1 24
$9.1M
$-62.5M
Free Cash Flow
CZWI
CZWI
LAB
LAB
Q4 25
$10.4M
Q3 25
$6.2M
$-23.1M
Q2 25
$-632.0K
$-22.6M
Q1 25
$1.5M
$-35.3M
Q4 24
$19.5M
Q3 24
$3.4M
$-30.1M
Q2 24
$4.8M
$-41.0M
Q1 24
$8.9M
$-63.3M
FCF Margin
CZWI
CZWI
LAB
LAB
Q4 25
65.9%
Q3 25
38.4%
-118.1%
Q2 25
-3.9%
-103.6%
Q1 25
10.7%
-86.6%
Q4 24
142.2%
Q3 24
23.8%
-136.4%
Q2 24
35.7%
-182.2%
Q1 24
58.9%
-138.9%
Capex Intensity
CZWI
CZWI
LAB
LAB
Q4 25
8.3%
Q3 25
2.4%
4.5%
Q2 25
1.4%
8.7%
Q1 25
0.7%
12.4%
Q4 24
6.5%
Q3 24
0.9%
10.2%
Q2 24
2.3%
8.6%
Q1 24
1.4%
1.7%
Cash Conversion
CZWI
CZWI
LAB
LAB
Q4 25
2.74×
Q3 25
1.80×
Q2 25
-0.12×
Q1 25
0.50×
Q4 24
7.55×
Q3 24
1.07×
Q2 24
1.39×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CZWI
CZWI

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons